The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Biosimilar Monoclonal Antibody-Global Market Insights and Sales Trends 2024
Synopsis
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.
The global Biosimilar Monoclonal Antibody market size is expected to reach US$ 5726.4 million by 2029, growing at a CAGR of 3.4% from 2023 to 2029. The market is mainly driven by the significant applications of Biosimilar Monoclonal Antibody in various end use industries. The expanding demands from the Chronic & Autoimmune Diseases, Oncology and Others,, are propelling Biosimilar Monoclonal Antibody market. Limited Dilution Method, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Micromanipulation segment is estimated at % CAGR for the next seven-year period.
Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.
Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.
In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Biosimilar Monoclonal Antibody, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Biosimilar Monoclonal Antibody market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Biosimilar Monoclonal Antibody market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Biosimilar Monoclonal Antibody sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Biosimilar Monoclonal Antibody covered in this report include Biocon, Accord Healthcare, AET Biotech, Amgen, Celltrion, Reddy's Laboratories, Hospira, 3SBio and Allergan, etc.
The global Biosimilar Monoclonal Antibody market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Biocon
Accord Healthcare
AET Biotech
Amgen
Celltrion
Reddy's Laboratories
Hospira
3SBio
Allergan
Alvartis
Global Biosimilar Monoclonal Antibody market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Biosimilar Monoclonal Antibody market, Segment by Type:
Limited Dilution Method
Micromanipulation
Soft Agar Plate Method
Others
Global Biosimilar Monoclonal Antibody market, by Application
Chronic & Autoimmune Diseases
Oncology
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Biosimilar Monoclonal Antibody companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.
The global Biosimilar Monoclonal Antibody market size is expected to reach US$ 5726.4 million by 2029, growing at a CAGR of 3.4% from 2023 to 2029. The market is mainly driven by the significant applications of Biosimilar Monoclonal Antibody in various end use industries. The expanding demands from the Chronic & Autoimmune Diseases, Oncology and Others,, are propelling Biosimilar Monoclonal Antibody market. Limited Dilution Method, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Micromanipulation segment is estimated at % CAGR for the next seven-year period.
Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.
Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.
In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Biosimilar Monoclonal Antibody, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Biosimilar Monoclonal Antibody market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Biosimilar Monoclonal Antibody market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Biosimilar Monoclonal Antibody sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Biosimilar Monoclonal Antibody covered in this report include Biocon, Accord Healthcare, AET Biotech, Amgen, Celltrion, Reddy's Laboratories, Hospira, 3SBio and Allergan, etc.
The global Biosimilar Monoclonal Antibody market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Biocon
Accord Healthcare
AET Biotech
Amgen
Celltrion
Reddy's Laboratories
Hospira
3SBio
Allergan
Alvartis
Global Biosimilar Monoclonal Antibody market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Biosimilar Monoclonal Antibody market, Segment by Type:
Limited Dilution Method
Micromanipulation
Soft Agar Plate Method
Others
Global Biosimilar Monoclonal Antibody market, by Application
Chronic & Autoimmune Diseases
Oncology
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Biosimilar Monoclonal Antibody companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Biosimilar Monoclonal Antibody
1.1 Biosimilar Monoclonal Antibody Market Overview
1.1.1 Biosimilar Monoclonal Antibody Product Scope
1.1.2 Biosimilar Monoclonal Antibody Market Status and Outlook
1.2 Global Biosimilar Monoclonal Antibody Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Biosimilar Monoclonal Antibody Market Size by Region (2018-2029)
1.4 Global Biosimilar Monoclonal Antibody Historic Market Size by Region (2018-2023)
1.5 Global Biosimilar Monoclonal Antibody Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Biosimilar Monoclonal Antibody Market Size (2018-2029)
1.6.1 North America Biosimilar Monoclonal Antibody Market Size (2018-2029)
1.6.2 Europe Biosimilar Monoclonal Antibody Market Size (2018-2029)
1.6.3 Asia-Pacific Biosimilar Monoclonal Antibody Market Size (2018-2029)
1.6.4 Latin America Biosimilar Monoclonal Antibody Market Size (2018-2029)
1.6.5 Middle East & Africa Biosimilar Monoclonal Antibody Market Size (2018-2029)
2 Biosimilar Monoclonal Antibody Market by Type
2.1 Introduction
2.1.1 Limited Dilution Method
2.1.2 Micromanipulation
2.1.3 Soft Agar Plate Method
2.1.4 Others
2.2 Global Biosimilar Monoclonal Antibody Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Biosimilar Monoclonal Antibody Historic Market Size by Type (2018-2023)
2.2.2 Global Biosimilar Monoclonal Antibody Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Biosimilar Monoclonal Antibody Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Biosimilar Monoclonal Antibody Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Biosimilar Monoclonal Antibody Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Biosimilar Monoclonal Antibody Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Biosimilar Monoclonal Antibody Revenue Breakdown by Type (2018-2029)
3 Biosimilar Monoclonal Antibody Market Overview by Application
3.1 Introduction
3.1.1 Chronic & Autoimmune Diseases
3.1.2 Oncology
3.1.3 Others
3.2 Global Biosimilar Monoclonal Antibody Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Biosimilar Monoclonal Antibody Historic Market Size by Application (2018-2023)
3.2.2 Global Biosimilar Monoclonal Antibody Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Biosimilar Monoclonal Antibody Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Biosimilar Monoclonal Antibody Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Biosimilar Monoclonal Antibody Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Biosimilar Monoclonal Antibody Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Biosimilar Monoclonal Antibody Revenue Breakdown by Application (2018-2029)
4 Biosimilar Monoclonal Antibody Competition Analysis by Players
4.1 Global Biosimilar Monoclonal Antibody Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biosimilar Monoclonal Antibody as of 2022)
4.3 Date of Key Players Enter into Biosimilar Monoclonal Antibody Market
4.4 Global Top Players Biosimilar Monoclonal Antibody Headquarters and Area Served
4.5 Key Players Biosimilar Monoclonal Antibody Product Solution and Service
4.6 Competitive Status
4.6.1 Biosimilar Monoclonal Antibody Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Biocon
5.1.1 Biocon Profile
5.1.2 Biocon Main Business
5.1.3 Biocon Biosimilar Monoclonal Antibody Products, Services and Solutions
5.1.4 Biocon Biosimilar Monoclonal Antibody Revenue (US$ Million) & (2018-2023)
5.1.5 Biocon Recent Developments
5.2 Accord Healthcare
5.2.1 Accord Healthcare Profile
5.2.2 Accord Healthcare Main Business
5.2.3 Accord Healthcare Biosimilar Monoclonal Antibody Products, Services and Solutions
5.2.4 Accord Healthcare Biosimilar Monoclonal Antibody Revenue (US$ Million) & (2018-2023)
5.2.5 Accord Healthcare Recent Developments
5.3 AET Biotech
5.3.1 AET Biotech Profile
5.3.2 AET Biotech Main Business
5.3.3 AET Biotech Biosimilar Monoclonal Antibody Products, Services and Solutions
5.3.4 AET Biotech Biosimilar Monoclonal Antibody Revenue (US$ Million) & (2018-2023)
5.3.5 Amgen Recent Developments
5.4 Amgen
5.4.1 Amgen Profile
5.4.2 Amgen Main Business
5.4.3 Amgen Biosimilar Monoclonal Antibody Products, Services and Solutions
5.4.4 Amgen Biosimilar Monoclonal Antibody Revenue (US$ Million) & (2018-2023)
5.4.5 Amgen Recent Developments
5.5 Celltrion
5.5.1 Celltrion Profile
5.5.2 Celltrion Main Business
5.5.3 Celltrion Biosimilar Monoclonal Antibody Products, Services and Solutions
5.5.4 Celltrion Biosimilar Monoclonal Antibody Revenue (US$ Million) & (2018-2023)
5.5.5 Celltrion Recent Developments
5.6 Reddy's Laboratories
5.6.1 Reddy's Laboratories Profile
5.6.2 Reddy's Laboratories Main Business
5.6.3 Reddy's Laboratories Biosimilar Monoclonal Antibody Products, Services and Solutions
5.6.4 Reddy's Laboratories Biosimilar Monoclonal Antibody Revenue (US$ Million) & (2018-2023)
5.6.5 Reddy's Laboratories Recent Developments
5.7 Hospira
5.7.1 Hospira Profile
5.7.2 Hospira Main Business
5.7.3 Hospira Biosimilar Monoclonal Antibody Products, Services and Solutions
5.7.4 Hospira Biosimilar Monoclonal Antibody Revenue (US$ Million) & (2018-2023)
5.7.5 Hospira Recent Developments
5.8 3SBio
5.8.1 3SBio Profile
5.8.2 3SBio Main Business
5.8.3 3SBio Biosimilar Monoclonal Antibody Products, Services and Solutions
5.8.4 3SBio Biosimilar Monoclonal Antibody Revenue (US$ Million) & (2018-2023)
5.8.5 3SBio Recent Developments
5.9 Allergan
5.9.1 Allergan Profile
5.9.2 Allergan Main Business
5.9.3 Allergan Biosimilar Monoclonal Antibody Products, Services and Solutions
5.9.4 Allergan Biosimilar Monoclonal Antibody Revenue (US$ Million) & (2018-2023)
5.9.5 Allergan Recent Developments
5.10 Alvartis
5.10.1 Alvartis Profile
5.10.2 Alvartis Main Business
5.10.3 Alvartis Biosimilar Monoclonal Antibody Products, Services and Solutions
5.10.4 Alvartis Biosimilar Monoclonal Antibody Revenue (US$ Million) & (2018-2023)
5.10.5 Alvartis Recent Developments
6 North America
6.1 North America Biosimilar Monoclonal Antibody Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Biosimilar Monoclonal Antibody Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Biosimilar Monoclonal Antibody Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Biosimilar Monoclonal Antibody Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Biosimilar Monoclonal Antibody Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Biosimilar Monoclonal Antibody Market Dynamics
11.1 Biosimilar Monoclonal Antibody Industry Trends
11.2 Biosimilar Monoclonal Antibody Market Drivers
11.3 Biosimilar Monoclonal Antibody Market Challenges
11.4 Biosimilar Monoclonal Antibody Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
